ARGX vs. BNTX, NBIX, TECH, QGEN, RGEN, BIIB, PCVX, EXEL, RVMD, and IBRX
Should you be buying argenx stock or one of its competitors? The main competitors of argenx include BioNTech (BNTX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), Biogen (BIIB), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.
BioNTech (NASDAQ:BNTX) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.
BioNTech has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.
argenx received 486 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 65.86% of users gave argenx an outperform vote while only 42.38% of users gave BioNTech an outperform vote.
BioNTech has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
BioNTech presently has a consensus price target of $111.70, indicating a potential upside of 23.28%. argenx has a consensus price target of $524.68, indicating a potential upside of 43.43%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe argenx is more favorable than BioNTech.
BioNTech has a net margin of 4.01% compared to BioNTech's net margin of -22.58%. argenx's return on equity of 0.55% beat BioNTech's return on equity.
In the previous week, argenx had 3 more articles in the media than BioNTech. MarketBeat recorded 19 mentions for argenx and 16 mentions for BioNTech. argenx's average media sentiment score of 0.93 beat BioNTech's score of 0.58 indicating that BioNTech is being referred to more favorably in the media.
15.5% of BioNTech shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 2.4% of argenx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
argenx beats BioNTech on 10 of the 19 factors compared between the two stocks.
Get argenx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
